Ohr Pharma's eye drug fails in mid-stage study, shares plunge

March 27, 2015 11:32 AM

15 0

(Reuters) - Ohr Pharmaceutical Inc said its experimental eye drug failed the main goal in a mid-stage study as a combination therapy, sending the company's shares plunging 64 percent in premarket trading on Friday.

The study tested the eye-drop solution, OHR-102, in combination with Roche Holding AG's injectable eye drug Lucentis, in patients with the wet age-related macular degeneration (AMD), the leading cause of blindness in the elderly.

Read more

To category page